What are the anatomic, functional, and oncologic criteria that define unresectability in the management of perihilar cholangiocarcinoma (Klatskin tumor)?

Unresectability Criteria for Perihilar Cholangiocarcinoma

Perihilar cholangiocarcinoma is unresectable when complete R0 resection cannot be achieved while leaving a functional liver remnant, specifically when there is bilateral secondary duct involvement with contralateral vascular encasement, distant metastases, or lymph node involvement beyond the hepatoduodenal ligament.

Anatomic Criteria for Unresectability

The most recent guideline 1 and supporting evidence 2 define resectability based on the ability to achieve complete tumor removal while preserving adequate liver function. A resectable pCCA requires complete disease resection while maintaining functional liver remnant in terms of volume, Glissonian pedicles, and venous drainage 2.

Vascular Involvement

Arterial encasement >180° is a major predictor of technical unresectability 3, with an 8-fold increased risk of non-resectability. The 2025 EASL guidelines 1 specify that:

• Circumferential contact, encasement (>180°), occlusion, stenosis, or contour deformity indicate unresectability
• Portal vein involvement can often be managed with reconstruction, but bilateral portal vein involvement with inadequate remnant is prohibitive
• Hepatic artery encasement carries worse prognosis than portal vein involvement due to smaller vessel caliber 1

Biliary Extent

Using the Bismuth-Corlette classification 4:

• Type IV tumors (bilateral secondary duct involvement) were historically considered unresectable, though select centers now report successful outcomes 5
• The critical factor is whether tumor-free margins can be achieved, not the Bismuth type alone

Liver Remnant Adequacy

Future liver remnant (FLR) volume <30% is associated with increased morbidity and mortality 2. Additional functional considerations include:

• Inadequate biliary drainage with FLR <50% increases risk 2
• Low indocyanine green clearance predicts poor outcomes 2
• Portal vein embolization requirement itself increases non-resectability risk 5-fold 3

Oncologic Criteria for Unresectability

Lymph Node Metastases

Lymph node involvement beyond the hepatoduodenal ligament (regional nodes) carries the same prognostic weight as visceral metastases and contraindicates resection 2. Specifically:

• Peripancreatic nodes along the body and tail are considered distant metastases 4
• Regional lymphadenectomy is mandatory, with removal of ≥5 lymph nodes recommended 2

Distant Metastases

Standard contraindications include 4:

• Peritoneal carcinomatosis (present in 10-20% at presentation)
• Liver metastases in contralateral lobe
• Extrahepatic organ involvement

Diagnostic laparoscopy should be performed in high-risk patients to identify peritoneal disease before laparotomy 3, as up to 50% of patients are lymph node positive at presentation 4.

Functional/Biological Criteria

The most recent evidence 6 demonstrates that biological markers significantly improve resectability assessment beyond anatomy alone:

CA 19-9 Levels

Elevated CA 19-9 ≥200 U/mL is an independent predictor of oncological non-resectability 3, 6, with:

• 3-fold increased risk of non-resectability 3
• Significantly worse recurrence-free survival even in anatomically resectable tumors 6

Preoperative Factors

Additional functional criteria affecting resectability 2:

• Preoperative bilirubin >50 μmol/L worsens outcomes
• Active cholangitis requiring drainage
• Age >70 years increases technical non-resectability risk 3.8-fold 3
• Severe malnutrition or decompensated liver disease

Algorithmic Approach to Resectability Assessment

Step 1: Exclude Distant Disease

• Multiphasic CT thorax-abdomen-pelvis 1
• Consider diagnostic laparoscopy if high-risk features present 3

Step 2: Assess Vascular Involvement

• MRI/MRCP with angiography 4, 1
• Arterial encasement >180° → likely unresectable
• Bilateral portal vein involvement → assess FLR adequacy

Step 3: Evaluate Biliary Extent

• MRCP to define secondary duct involvement 1
• Assess ability to achieve R0 margins (goal: 5-10mm) 4, 2

Step 4: Calculate Functional Reserve

• FLR volume (must be ≥30%) 2
• Consider portal vein embolization if borderline
• Assess liver function (bilirubin, ICG clearance) 2

Step 5: Integrate Biological Factors

• CA 19-9 level (≥200 U/mL indicates high-risk biology) 3, 6
• Lymph node status on imaging 1

Critical Pitfalls to Avoid

1. Do not perform routine preoperative biliary drainage 4 except for acute cholangitis or severe malnutrition, as it increases infection risk without improving outcomes

2. Portal vein resectability does not equal oncologic benefit - while technically feasible, portal vein resection has not demonstrated survival improvement in most series 7

3. Anatomic resectability alone is insufficient - the anatomic-biologic borderline resectable framework 6 demonstrates that CA 19-9 ≥200 U/mL reclassifies risk even in anatomically resectable tumors

4. Avoid transperitoneal biopsy 2 due to tumor seeding risk; diagnosis can be established at time of resection in resectable cases

Special Considerations

Liver transplantation may be considered for highly selected unresectable cases 4, 2, 8 using Mayo Clinic protocol criteria:

• No lymph node involvement
• Tumor diameter <3 cm
• No transperitoneal biopsy
• Completion of neoadjuvant chemoradiation
• Underlying PSC or hepatopathy precluding major hepatectomy

However, standard liver transplantation remains contraindicated outside clinical trials 4 due to high recurrence rates.

The goal of surgery must be R0 resection 2, as R1 margins significantly worsen both overall and recurrence-free survival. Palliative resection is not recommended 4.